Neuropore Therapies, Inc. announced today that partner UCB initiated a multicenter clinical trial in Parkinson’s disease patients with UCB0599 in the United States of America. UCB0599, an alpha-synuclein misfolding inhibitor, is a therapeutic candidate arising from...
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that GtreeBNT (‘Gtree’), its licensee...
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors, today announces that the last patient has been included in the Phase 2 trial evaluating TG4010 in combination with Opdivo® (nivolumab) and...
Isabelle Richard’s team, a CNRS researcher in an Inserm unit at Genethon, the AFM-Telethon laboratory, has demonstrated the efficacy of gene therapy and determined the effective dose for treating a rare muscle disease, gamma-sarcoglycanopathy, in mouse models of...
by Deborah Mann Lake, University of Texas Health Science Center at Houston writes: Something as simple as a phone call could be a way to alert health care providers and caregivers that an elderly person suffering from dementia may be spiraling down to dangerous...
Promising anti-aging stem cell therapy AR-100 shows potential in the treatment of age-related diseases Rejenevie™ Therapeutics announced the commencement of the company’s Phase II clinical trial to study the safety and effectiveness of its proprietary AR-100...
Email
Text